Clinical Trial: IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia

U.S., April 4 -- ClinicalTrials.gov registry received information related to the study (NCT07509086) titled 'IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia' on Feb. 21.

Brief Summary: This is an open-label, single-arm, Phase 2 study to evaluate the efficacy and safety of IL-15-armored chimeric antigen receptor T-cell (CAR-T) therapy in subjects with relapsed or refractory multiple myeloma and plasma cell leukemia.

Study Start Date: Dec. 29, 2025

Study Type: INTERVENTIONAL

Condition: Relapsed/Refractory Multiple Myeloma Plasma Cell Leukemia (PCL)

Intervention: BIOLOGICAL: IL-15-armored CAR-T cells

BCMA-targeted: 1.0/1.5/2.0 x 10^6 CAR-T cells; CD19/BCMA dual-targeted: 1.0/1.5/2.0 x 10^...